Rich and poor nations lock horns over vaccine patents at WTO
Proposal is backed by dozens of largely developing countries but opposed by Western countries including Britain, Switzerland, EU nations and the US
Geneva — A push to increase production of Covid-19 vaccines for poor nations hung in the balance at the World Trade Organization on Wednesday amid disagreement between richer and developing countries over the issue of patent rights.
SA and India planned to renew their bid at a two-day meeting to waive rules of the WTO’s Trade-Related Aspects of Intellectual Property Rights (Trips) agreement, a move that would allow generic or other manufacturers to make more vaccines.
Their proposal is backed by dozens of largely developing countries at the WTO, but opposed by Western countries including Britain, Switzerland, EU nations and the US, which have large domestic pharmaceutical industries.
Proposals need backing by a consensus of the WTO’s 164 members to pass.
The issue was set to come up at the WTO’s Trips Council on Wednesday. Members were due to hold an eighth discussion on the topic since it was first raised in October.
Ngozi Okonjo-Iweala, who became WTO director-general on March 1, called the intensifying Trips discussions “vitally important”, but said governments and businesses needed to act now to increase production, especially in emerging markets.
She said in a speech on Tuesday that manufacturers should come together with bodies such as the WHO and vaccines alliance Gavi, whose board she used to chair, and business associations to look into options.
“We must make sure that in the end we deliver so that the millions of people who are waiting for us with bated breath know that we are working on concrete solutions,” the former Nigerian finance and foreign minister said.
The next Trips Council meeting is set for June 8-9, but the group will probably be convened again to discuss vaccines before then.
Would you like to comment on this article or view other readers' comments?
Register (it’s quick and free) or sign in now.
Please read our Comment Policy before commenting.